EGFR and non-small cell lung carcinoma: Based on KEYNOTE‐042 (NCT02220894), pembrolizumab is approved as the first-line treatment of stage III NSCLC patients with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic aberrations, while also the tumour must express PD-L1 (TPS ≥1%) [42].